Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SGHT 
Sight Sciences Inc (SGHT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SGHT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.33
1 Year Target Price $4.33
| 2 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.48% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 180.67M USD | Price to earnings Ratio - | 1Y Target Price 4.33 |
Price to earnings Ratio - | 1Y Target Price 4.33 | ||
Volume (30-day avg) 8 | Beta 2.41 | 52 Weeks Range 2.03 - 5.94 | Updated Date 10/17/2025 |
52 Weeks Range 2.03 - 5.94 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -64.23% | Operating Margin (TTM) -59.63% |
Management Effectiveness
Return on Assets (TTM) -22.4% | Return on Equity (TTM) -57.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 112405958 | Price to Sales(TTM) 2.37 |
Enterprise Value 112405958 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA -4.25 | Shares Outstanding 52367359 | Shares Floating 28877980 |
Shares Outstanding 52367359 | Shares Floating 28877980 | ||
Percent Insiders 20.53 | Percent Institutions 50.34 |
Upturn AI SWOT
Sight Sciences Inc
Company Overview
History and Background
Sight Sciences, Inc. was founded in 2011. It is a growth-stage medical device company transforming the two largest and fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease.
Core Business Areas
- Glaucoma: Sight Sciences develops and commercializes surgical and non-surgical solutions for glaucoma management. Their products aim to lower intraocular pressure (IOP) by improving the eye's natural drainage pathways.
- Dry Eye Disease: The company offers products and technologies to treat dry eye disease by addressing underlying causes and improving tear film stability.
Leadership and Structure
Paul Badawi is the Co-Founder and CEO. The company has a typical corporate structure with departments like R&D, marketing, sales, and operations, all reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- OMNI Surgical System: A microcatheter-based system used in minimally invasive glaucoma surgery (MIGS) to treat various types of glaucoma. OMNI provides access to all three points of outflow resistance, Trabecular Meshwork, Schlemmu2019s canal and distal collector channels. Market share data is still growing for the company. Competitors include Glaukos (GKOS) with iStent, New World Medical with Ahmed Glaucoma Valve, and Alcon (ALC) with CyPass (although CyPass has been withdrawn from the market).
- TearCare System: A non-surgical, office-based procedure for treating dry eye disease by applying localized heat to the meibomian glands. The TearCare System is used in conjunction with manual expression of the glands. Market share data is still growing for the company. Competitors include Johnson & Johnson (JJNJ) with LipiFlow, Lumenis with Intense Pulsed Light (IPL), and Allergan (ABBV) with Restasis/Xiidra (medications).
Market Dynamics
Industry Overview
The ophthalmology market is experiencing growth due to the aging population and increasing prevalence of glaucoma and dry eye disease. The dry eye disease market is experiencing rapid growth. There is a growing trend towards minimally invasive procedures.
Positioning
Sight Sciences is positioned as an innovator in both the glaucoma and dry eye markets, offering solutions that address underlying causes and improve patient outcomes. They are focusing on expanding market share and gaining wider adoption of their technologies. They aim to improve outcomes for patients with the best surgical and non-surgical solutions.
Total Addressable Market (TAM)
The TAM for glaucoma and dry eye is estimated to be in the billions of dollars globally. Sight Sciences is positioned to capture a significant portion of this market by expanding the market and increasing market share through innovation and commercial execution.
Upturn SWOT Analysis
Strengths
- Innovative products addressing large markets
- Strong IP portfolio
- Experienced management team
- Focus on clinical evidence
Weaknesses
- Limited commercial reach compared to larger competitors
- Reliance on reimbursement approvals
- Relatively young company with limited operating history
- Not profitable
Opportunities
- Expanding into new geographic markets
- Developing new products and applications
- Increasing awareness and adoption of their technologies
- Acquiring complementary technologies or companies
Threats
- Competition from established players
- Changes in reimbursement policies
- Technological advancements that could render their products obsolete
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- GKOS
- ALC
- JNJ
- ABBV
Competitive Landscape
Sight Sciences competes with larger, more established companies in the ophthalmology market. Their competitive advantage lies in their innovative products and focus on addressing underlying causes of disease.
Growth Trajectory and Initiatives
Historical Growth: Sight Sciences has experienced revenue growth, driven by increased adoption of its OMNI and TearCare systems.
Future Projections: Analysts project continued revenue growth for Sight Sciences, driven by expansion into new markets and increased adoption of their technologies. Profitability is expected to improve in the coming years.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in R&D, and pursuing strategic partnerships and acquisitions.
Summary
Sight Sciences is a growth-stage medical device company with innovative products in the glaucoma and dry eye markets. They are experiencing revenue growth, but are not yet profitable and are burning cash. They face competition from larger, established players. Future success depends on continued innovation, successful commercial execution, and achieving profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sight Sciences Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2021-07-15 | Co-Founder, President, CEO & Director Mr. Paul Badawi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 216 | Website https://www.sightsciences.com |
Full time employees 216 | Website https://www.sightsciences.com | ||
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.